Á¦8Â÷ ±¹¸³¾Ï¼¾ÅÍ ¾Ï°úÇÐÆ÷·³ T cell engager ÇöÀç¿Í ¹Ì·¡ : 2023-09-14
±³À°ÀÏÀÚ : 2023-09-14
±³À°Àå¼Ò : ±¹¸³¾Ï¼¾ÅÍ °ËÁøµ¿ 8Ãþ ±¹Á¦È¸ÀÇÀå
±³À°ÁÖÁ¦ : (¿Â-¿ÀÇÁº´Çà)Á¦8Â÷ ±¹¸³¾Ï¼¾ÅÍ ¾Ï°úÇÐÆ÷·³ T cell engager ÇöÀç¿Í ¹Ì·¡
ÁÖÃÖ±â°ü : ±¹¸³¾Ï¼¾ÅÍ
´ã´çÀÚ : ±èµÎȯ
¿¬¶ôó : 031-920-1587
À̸ÞÀÏ : ncch5@ncc.re.kr
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¹æ»ç¼±Á¾¾çÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, ¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀÎ : 300¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : °æ±âµµ
±³À°½Ã°£ : 3 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 09¿ù 14ÀÏ °ËÁøµ¿ 8Ãþ ±¹Á¦È¸ÀÇÀå 13:10~13:15 °³È¸ ±è¿µ¿ì(±¹¸³¾Ï¼¾ÅÍ ¿¬±¸¼ÒÀå)
±âŸ 09¿ù 14ÀÏ °ËÁøµ¿ 8Ãþ ±¹Á¦È¸ÀÇÀå 13:15~13:20 Ãà»ç ¼È«°ü(±¹¸³¾Ï¼¾ÅÍ ¿øÀå)
±³À°½Ã°£ 09¿ù 14ÀÏ °ËÁøµ¿ 8Ãþ ±¹Á¦È¸ÀÇÀå 13:20~14:10 BiTE Technology and Recent Developments with Blinatumomab and Tarlatamab Matthias Klinger(Director Research. Amgen Research Munich )
±³À°½Ã°£ 09¿ù 14ÀÏ °ËÁøµ¿ 8Ãþ ±¹Á¦È¸ÀÇÀå 14:10~15:00 Grabody T, 4-1BB Bispecific Antibodies at ABL Bio Á¤ÀçÈ£(ABL Bio º»ºÎÀå)
ÈÞ½Ä 09¿ù 14ÀÏ °ËÁøµ¿ 8Ãþ ±¹Á¦È¸ÀÇÀå 15:00~15:20 ÈÞ½Ä ()
±³À°½Ã°£ 09¿ù 14ÀÏ °ËÁøµ¿ 8Ãþ ±¹Á¦È¸ÀÇÀå 15:20~16:00 Bispecific Antibodies in Hematologic Malignancies Zhu Yan(Janssen AP Medical Director for Bispecific Antibodies)
±³À°½Ã°£ 09¿ù 14ÀÏ °ËÁøµ¿ 8Ãþ ±¹Á¦È¸ÀÇÀå 16:00~16:40 Odronextamab in Patients with R/R FL and DLBCL: Results from a Prespecified Analysis of the Pivotal Phase 2 Study ELM-2. Srikanth Ambati (Sr. Medical Director, Clinical Sciences, Regeneron)
±³À°½Ã°£ 09¿ù 14ÀÏ °ËÁøµ¿ 8Ãþ ±¹Á¦È¸ÀÇÀå 16:40~17:20 Ç÷¾×¾Ï¿¡¼ÀÇ CD3 Bispecific Antibody ¿ªÇÒ; ÇöÀç¿Í ¹Ì·¡ ÀÌÇý¿ø(±¹¸³¾Ï¼¾ÅÍ Ç÷¾×Á¾¾ç³»°úºÐ°ú)
±âŸ 09¿ù 14ÀÏ °ËÁøµ¿ 8Ãþ ±¹Á¦È¸ÀÇÀå 17:20~17:30 Æóȸ ±è¿µ¿ì(±¹¸³¾Ï¼¾ÅÍ ¿¬±¸¼ÒÀå)